The pivotal PROTECT VIII trial was designed to reflect real-world treatment1

Jivi® dosing was tailored to patients' bleeding tendencies2

Study Design Chart
At the end of the main study:
97%
of patients opted into the long-term extension study2‡
  • 112 patients entered prophylactic treatment arms; an additional 20 patients entered a control arm of on-demand treatment. Two patients in the prophylactic arms left the main study prematurely during the run-in period.2
  • Defined as joint or muscle bleeds and no identified trauma.1,2
  • n=107/110 prophylaxis patients from the main study opted into the extension study.2